Media about us

• Production of one of the world’s most sought-after drugs for migraine therapy starts in Moscow

  13 July 2023 PharmProm.net

  

  The Russian pharmaceutical company NovaMedica has announced the production and market launch of the first large batch of the drug Relonova® intended for relief of migraine-associated headaches. The drug is based on the Rizatriptan molecule, which for the first time is fully localized in Russia, from development and manufacturing to introduction in the specialist prescription practice. Rizatriptan is one of the most sought-after molecules in the world for relief and alleviation of migraine symptoms.

• Production of one of the world’s most sought-after drugs for migraine therapy starts in Moscow

  12 July 2023 GxPnews

  

  The Russian pharmaceutical company NovaMedica has announced the production and market launch of the first large batch of the drug Relonova intended for relief of migraine-associated headaches. The drug is based on the Rizatriptan molecule, which for the first time is fully localized in Russia, from development and manufacturing to introduction in the specialist prescription practice. Rizatriptan is one of the most sought-after molecules in the world for relief and alleviation of migraine symptoms.

• Vascular Dementia Treatment Market Size Projected to Grow US$ 8.99 Billion by 2033 | Exclusive Report by Future Market Insights, Inc.

  12 April 2023 Future Market Insights

  

  According to a recent report published by Future Market Insights, The projected growth for vascular dementia treatment market indicates an increase in market value to US$ 5.64 billion in FY 2023, reflecting a year-on-year rise of over 5%. Moreover, the market is expected to grow at a compound annual growth rate (CAGR) of 4.77% during the forecast period from 2023 to 2033, with an estimated market value of US$ 8.99 billion by FY 2033.

• NovaMedica will produce migraine drug Relonova in Moscow

  23 March 2023 GxPnews

  

  Russia’s pharmaceutical company NovaMedica (a Rusnano portfolio company) has registered Relonova, a drug of its own development, used to relieve headaches during migraine attacks. This is the first rizatriptan-based drug fully localized in the Russian Federation, as the company’s press service told GxP News.

• RUSNANO has stopped the exit from a number of critically important assets for the country

  10 June 2022 AKM Informational agency

  

  RUSNANO has stopped the withdrawal from a number of critically important assets for the country, which contribute to the provision of infrastructure and form a technological reserve for the Russian industry in mechanical engineering, medicine, chemistry, oil and gas, lighting and electronics, telecommunications, energy, transport and housing. Among them are the companies "Plakart", "Virial", "Optical Fiber Systems", "RM Nanotech", "Profotek", "Russian Quartz", "NEVZ-CERAMICS", "Novomet", "ELVIS NeoTek", "ICE-Energoservice", "NovaMedica", "Pharmsintez" and a number of projects of the RUSNANO-SINTEZ Foundation.

• Technopolis Moscow has begun to produce a therapy for dementia

  26 April 2022 GxPnews

  

  Technopolis Moscow has begun the production of a new therapy for dementia in Alzheimer’s disease, available in the form of tablets in four dosages. This is reported on the official website of the mayor of Moscow.

• NovaMedica launches an innovative Alzheimer’s disease therapy that it has developed

  21 April 2022 GxPnews

  

  NovaMedica, a Russian pharmaceutical company (Rusnano’s investment project) has developed and registered an innovative combination of donepezil and memantine molecules, which provides the basis for dementia therapy in Alzheimer’s disease. The drug is registered as MYOREOL^®. This is the first combination of this type on the Russian market, as well as in the EAEU and Europe.

• Producers criticize excessive pharma market regulation in Russia

  28 September 2021 The Pharma Letter

  

  Excessive regulation of the Russian pharmaceutical market and the lack of drug insurance system is leading to a shortage of some vital and effective drugs in the local market, according to recent statements by representatives of producers and analysts. 

• New Russian proctology medicine makes inroads in EU markets

  26 July 2021 Marchmont Innovation News

  

  NovaMedica, a Russian pharmaceutical company and portfolio project of the national nanotech company Rusnano, has developed what might emerge into a market-winning new drug for colorectal therapy.

• Bayer found a pill

  31 May 2021 ScoopTrade

  

  Concern Bayer will expand its portfolio of drugs for the treatment of hemorrhoids with the development of the Russian “NovaMedica” based on nifedipine and lidocaine. The German company already holds about 40% of the market for such funds. Pharmaceutical market experts call the deal one of the rare ones: foreign companies do not often acquire rights to Russian medicines.